Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

2020-03-24
Price :
Published : Mar-2020
No. of Pages : 184

The global biosimilars  market size is projected to register a CAGR of 24.7% during the forecast period.

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market.

“The monoclonal antibody segment is anticipated to grow at the fastest growth rate during the forecast period.”

The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, and teriparatide and enoxaparin sodium. The monoclonal antibodies segment is expected to register the highest CAGR during the forecast period. The growth of this segment is driven mainly by the increasing number of product launches/approvals, rising incidences of cancer diseases.

“The contract manufacturing  segment is estimated to grow at a rapid rate during the analysis period.”

Based on the treatment site, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to remain the fastest-growing segment of the global market during the biosimilars period. Its benefits, particularly for small players in the market or those that do not have sufficient infrastructure and resources for efficient manufacturing, are driving growth.

“Asia Pacific is estimated to register the highest CAGR during the study period.”

Geographically, the biosimilars market is dominated by Europe and followed by Asia Pacific in 2019. However, the Asia Pacific region is estimated to grow at the fastest rate during forecast to period. The rising aging population, coupled with the massive demand for cost-effective alternative pharmaceuticals, will drive the market in the region over the forecast period.

Breakdown of Profiles of Primary Participants:

  • By Company Type: Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
  • By Designation: C-level: 30%, Director-level: 34%, and Others: 36%
  • By Region: North America: 40%, Europe: 28%, Asia Pacific: 20%, and the Rest of the World: 12%

The key players in the biosimilars market include Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), Fresenius Kabi AG (Germany),  Boehringer Ingelheim (Germany), Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy’s Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany).

Research Coverage:

The report analyzes the biosimilars market by product, type of manufacturing, indication, and region. Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key Benefits of Buying the Report:

This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any one, or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the services of the top players in the biosimilars market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
  • Market Development: Detailed information about emerging markets.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market
Filed in: Pharmaceutical
Publisher : marketsandmarkets
More Reports
Title Price Buy Now

Impact on Publicly Traded Bio/Pharma Companies – Coronavirus Disease (COVID-19) 2019 Impact Report

Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization. Scope - This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how the top 20 Mega Cap Bio/Pharma Companies have been affected, and will continue to be affected, by the COVID-19 pandemic.......
$695

Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2029

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029 Summary Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. Until recently, chemotherapy and hypomethylating agents were the only treatment options, but since 2017 this has changed with the introduction of premium-priced novel therapies. The global AML market is expected to grow from $1.4B in 2019 to $5.1B in 2029 at a compound annual growth rate (CAGR) of 13.6%. This dramatic growth is driven by the launch of 16 new pipeline agents in the 7MM and 12 in China, by the......
$10995

Acute Myeloid Leukemia – Epidemiology Forecast to 2029

Acute Myeloid Leukemia - Epidemiology Forecast to 2029 Summary Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow in which the bone marrow produces abnormal red blood cells, white blood cells, or platelets, and generally progresses at a rapid pace. AML is more common in the elderly, is associated with severe complications and high mortality, and accounts for a disproportionately high number of cancer-related deaths. AML is often called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. In 2019, there were 72,164 diagnosed incident cases of AML in the 8MM in men and women combined for ages 18 years and older. GlobalData epidemiologists estimate that globally, cases will rise to 90,264 at an Annual Gr......
$3995

Aseptic Sampling Market by Type (Manual [Type (Traditional, Single-use), Product (Bags, Bottles, Syringes, Accessories)], Automatic), Application (Upstream, Downstream), Technique (Off-line, On-line), End User (R&D, CMO, CRO) – Global Forecast to 2025

 “The aseptic sampling market is projected to grow at a CAGR of 12.4% during the forecast period (2020–2025).” The global aseptic sampling market size is projected to reach USD 474 million by 2025 from USD 264 million in 2020, at a CAGR of 12.4%. The growth of this market is driven majorly by factors such as the increasing demand for biopharmaceuticals, stringent government regulations to ensure drug safety, and funding to support life sciences research activities. On the other hand, issues related to leachables and extractable from single-use products are restraining market growth. “By type, the manual aseptic sampling segment is expected to grow at the highest CAGR during the forecast period.” Based on type, the aseptic sampling market is segmented into manual aseptic......
$4950

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussing online about the virus. Scope The report includes 10 Influencers - - Eight therapy areas: Cardiovascular, Metabolic Disord......
$995

Digital Biomarkers – Coronavirus Disease 2019 (COVID-19) Case Study

Digital Biomarkers - Coronavirus Disease 2019 (COVID-19) Case Study Summary The ongoing COVID-19 crisis has seen social distancing and lockdown measures implemented around the world, which has had widespread effects on the healthcare industry, particularly in the ways that patients and healthcare professionals can safely interact while minimizing risks of viral transmission. Remote patient monitoring and the collection of digital biomarkers by connected devices has emerged as an important approach to support patients and healthcare systems during the pandemic. This case study assesses how connected devices and digital biomarkers can be used during the COVID-19 pandemic and beyond. Key Highlights - Digital biomarkers are an important addition to the armamentarium of tools supporting pa......
$595

Animal Parasiticides Market by Product (Ectoparasiticides, Endectocide (Ear Tags, Tablets, Dips, Injectables, Spot-on, Collars) Animal (Dogs, Cats, Cattle, Sheep, Goats, Horses) End-user (Veterinary Hospitals) – Global Forecast to 2025

“The animal parasiticides market is projected to grow at a CAGR of 7.2% between 2020 and 2025.” The animal parasiticides market is expected to reach USD 13.7 billion by 2025 from USD 9.7 billion in 2020, at a CAGR of 7.2% from 2020 to 2025. Increasing pet expenditure and the growing incidences of parasitic infections are some major factors driving the market. However, accounting for the diversity of parasitic species while developing effective medications and parasiticides is one of the major challenges for players operating in this market. “Ecto parasiticides segment to witness the highest growth rate during the forecast period.” In the market, by type, ecto parasiticides are expected to register the highest CAGR during the forecast period. The high growth of this segment......
$4950

Health Insurance Implications – Coronavirus Disease (COVID-19) Sector Impact – June 2020

Health Insurance Implications - Coronavirus Disease (COVID-19) Sector Impact - June 2020 Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. The virus is also having a growing impact on the global economy including the health insurance industry. This report reflects how government bodies and healthcare authorities are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis. Key Highlights - A number of reports estimated the impact of COVID-19 on unemployment rates and loss of E......
$495

Laboratory Information Management System (LIMS) Market by Type (Broad, Industry-specific), Component (Software, Services), Delivery (On premise, Remote, Cloud), End User (CRO, Pharma, Biotech, Chemical, Agriculture, FnB, Oil, Gas) – Global Forecast to 2025

“The global laboratory information management systems market is projected to grow at a CAGR of 12.1% during the forecast period (2020–2025)” The global LIMS market is estimated to reach USD 1.7 billion by 2025 from USD 1.0 billion in 2020, at a CAGR of 12.1%. The increasing adoption of LIMS to comply with stringent regulatory requirements, technological advancements in LIMS offerings, increasing R&D expenditure in pharmaceutical and biotechnology companies, and the growing adoption of cloud-based LIMS are some of the factors driving the growth of this market. However,the high maintenance and service costs and the lack of integration standards for LIMS are expected to restrain the growth of this market. “Services segment to grow at the highest CAGR during the forecast peri......
$4950

Non-Alcoholic Steatohepatitis – Epidemiology Forecast to 2029

Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029 Summary Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2016). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem (NIDDK, 2016). GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of NASH. For all the 7MM, NASH cas......
$3995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy